Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Birch pollen extract combined with ragweed pollen extract is a form of allergen-specific immunotherapy (AIT) used to treat individuals with co-sensitization to both types of pollen. This therapy, often administered as subcutaneous injections (allergy shots), works by gradually exposing the patient's immune system to controlled doses of the allergens. The goal is to induce immunological tolerance, shifting the immune response from an allergic (Th2-dominated) to a non-allergic (Th1/Treg-dominated) state. This process reduces the severity of allergic rhinitis and/or asthma symptoms upon natural exposure to birch and ragweed pollen and can decrease the need for symptom-relieving medications. Clinical studies have demonstrated its effectiveness in both younger and older patient populations with a history of inadequately controlled allergies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on birch pollen extract + ragweed pollen extract.